Development of novel bioanalytical methods to determine the effective concentrations of phosphorodiamidate morpholino oligomers in tissues and cells

BioResearch Open Access

Volumn 2, Issue 1, 2013, Pages 61-66

  Schnell, Frederick J ^a   Crumley, Stacy L ^a   Mourich, Dan V ^a,b   Iversen, Patrick L ^a  

^a AVI BIOPHARMA INC   (United States)

^b OREGON STATE UNIVERSITY   (United States)

Author keywords

drug discovery; gene regulation; nucleic acids; virology

Indexed keywords

MORPHOLINO OLIGONUCLEOTIDE;

ANALYTICAL EQUIPMENT; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; DRUG CLEARANCE; DRUG DETERMINATION; DRUG TISSUE LEVEL; DRUG UPTAKE; FEMALE; FLOW CYTOMETRY; FLUORESCENCE IN SITU HYBRIDIZATION; HEMATOPOIETIC CELL; HYBRIDIZATION; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; OLIGONUCLEOTIDE PROBE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; SANDWICH HYBRIDIZATION;

ORTHOMYXOVIRIDAE;

EID: 84887324689     PISSN: None     EISSN: 21647860     Source Type: Journal    
DOI: 10.1089/biores.2012.0276     Document Type: Article

References (14)

1. Summerton J, Weller D. Morpholino antisense oligomers: design, preparation, and properties. Antisense Nucleic Acid Drug Dev. 1997;7:187-195.
2. Ghosh C, Stein D, Weller D, Iversen P. Evaluation of antisense mechanisms of action. Methods Enzymol. 2000;313: 135-143.
3. Sazani P, Kole R. Therapeutic potential of antisense oligonucleotides as modulators of alternative splicing. J Clin Invest. 2003;112:481-486.
4. Warren TK, Warfield KL, Wells J, et al. Advanced antisense therapies for postexposure protection against lethal filovirus infections. Nat Med. 2010;16:991-994.
5. Kinali M, Arechavala-Gomeza V, Feng L, et al. Local restoration of dystrophin expression with the morpholino oligomer AVI-4658 in Duchenne muscular dystrophy: a single-blind, placebo-controlled, dose-escalation, proof-of-concept study. Lancet Neurol. 2009;8:918-928.
6. Iversen PL, Arora V, Acker AJ, et al. Efficacy of antisense morpholino oligomer targeted to c-myc in prostate cancer xenograft murine model and a Phase I safety study in humans. Clin Cancer Res. 2003;9:2510-2519.
7. Sazani P, Ness KP, Weller DL, et al. Chemical and mechanistic toxicology evaluation of exon skipping phosphorodiamidate morpholino oligomers in mdx mice. Int J Toxicol. 2011; 30:322-333.
8. Sazani P, Weller DL, Shrewsbury SB. Safety pharmacology and genotoxicity evaluation of AVI-4658. Int J Toxicol. 2010;29:143-156.
9. Marshall NB, Oda SK, London CA, et al. Arginine-rich cellpenetrating peptides facilitate delivery of antisense oligomers into murine leukocytes and alter pre-mRNA splicing. J Immunol Methods. 2007;325:114-126.
10. Arora V, Devi GR, Iversen PL. Neutrally charged phosphorodiamidate morpholino antisense oligomers: uptake, efficacy and pharmacokinetics. Curr Pharm Biotechnol. 2004;5: 431-439.
11. Efler SM, Zhang L, Noll BO, et al. Quantification of oligodeoxynucleotides in human plasma with a novel hybridization assay offers greatly enhanced sensitivity over capillary gel electrophoresis. Oligonucleotides. 2005;15: 119-131.
12. Moulton HM, Wu B, Jearawiriyapaisarn N, et al. Peptidemorpholino conjugate: a promising therapeutic for Duchenne muscular dystrophy. Ann NY Acad Sci. 2009;1175: 55-60.
13. Swenson DL, Warfield KL, Warren TK, et al. Chemical modifications of antisense morpholino oligomers enhance their efficacy against Ebola virus infection. Antimicrob Agents Chemother. 2009;53:2089-2099.
14. Reed L, Meunch H. A simple method of estimating fifty percent endpoints. Am J Hygiene 1838;27:493-497.